1. Home
  2. KNOP vs FULC Comparison

KNOP vs FULC Comparison

Compare KNOP & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KNOT Offshore Partners LP

KNOP

KNOT Offshore Partners LP

N/A

Current Price

$7.99

Market Cap

302.0M

ML Signal

N/A

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

N/A

Current Price

$3.72

Market Cap

281.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KNOP
FULC
Founded
2013
2015
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
302.0M
281.1M
IPO Year
2012
2019

Fundamental Metrics

Financial Performance
Metric
KNOP
FULC
Price
$7.99
$3.72
Analyst Decision
Strong Buy
Hold
Analyst Count
2
5
Target Price
★ $14.50
$3.67
AVG Volume (30 Days)
112.9K
★ 1.2M
Earning Date
12-03-2026
11-12-2026
Dividend Yield
★ 5.01%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$0.65
N/A
Revenue Next Year
$0.75
N/A
P/E Ratio
$9.00
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.89
$2.83
52 Week High
$11.78
$15.74

Technical Indicators

Market Signals
Indicator
KNOP
FULC
Relative Strength Index (RSI) 25.84 48.54
Support Level N/A $3.62
Resistance Level $10.82 $3.79
Average True Range (ATR) 0.53 0.06
MACD -0.06 0.00
Stochastic Oscillator 4.42 43.75

Price Performance

Historical Comparison
KNOP
FULC

About KNOP KNOT Offshore Partners LP

KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: